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Introduction: Juvenile idiopathic arthritis (JIA) is a disease associated with loss of bone mass, deterioration in bone
mass quality and an increased risk of fractures. The objective of this study was to evaluate factors that predict bone
mineral density (BMD) alterations in young adult patients with active JIA before and during therapy with tumour
necrosis factor α (TNFα) inhibitors.
Methods: Thirty-one patients (twelve males and nineteen females; mean age =25.1 ± 6.1 years) with active JIA (mean
Disease Activity Score in 28 joints (DAS28) =6.36 ± 0.64; mean high-sensitivity C-reactive protein (hsCRP) =18.36 ±
16.95 mg/L) were investigated. The control group consisted of 84 healthy individuals matched by sex and age. BMD,
bone turnover markers and serum concentrations of soluble receptor activator of nuclear factor κB ligand,
osteoprotegerin, dickkopf Wnt signalling pathway inhibitor 1 (Dkk1) and sclerostin were evaluated.
Results: Baseline BMD values in the lumbar spine, proximal femur, femoral neck and distal radius were significantly lower
in patients with JIA compared to healthy control participants. Baseline sclerostin serum concentrations were significantly
higher in patients with JIA compared to control participants. After 2 years of treatment with TNFα inhibitors, BMD was
significantly increased in the lumbar spine. This increase correlated with a drop in DAS28 score. A statistically significant
correlation between hsCRP and Dkk1 was found at baseline, as well as during the 2-year follow-up period. A significant
reduction in serum sclerostin after 1 year of therapy was predictive of a drop in DAS28 score observed with a 1-year delay
after reduction of serum sclerostin.
Conclusion: A significant correlation between the sclerostin serum concentration and the number of tender and swollen
joints, but not BMD, supports the hypothesis that chondrocytes and cells of the subchondral bone may contribute to
circulating sclerostin in JIA.Introduction
Juvenile idiopathic arthritis (JIA) is a systemic autoimmune
inflammatory connective tissue disease with onset occur-
ring before age 16 years. It is associated with a decrease in
bone mass, thinning of the cortical bone [1,2], sarcopenia
[3,4] and an increased risk of fractures [5]. Bone loss may
be systemic or localized to the periarticular bone due to
arthritis of the affected joint. The pathophysiology of the
bone mass loss may involve, in particular, the negative ef-
fect of proinflammatory cytokines, as well as treatment with
glucocorticoids [6]. Thus, the loss of bone mass may reflect
a disorder of bone modelling and remodelling. This process
involves proinflammatory cytokines produced by the* Correspondence: stepan@revma.cz
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article, unless otherwise stated.synovial membrane, which may increase bone resorption
but also stimulate soluble antagonists of the canonical
Wnt/β-catenin signalling pathway, including dickkopf Wnt
signalling pathway inhibitor 1 (Dkk1) and sclerostin, and
subsequently inhibit osteoblast proliferation, maturation
and progenitor differentiation [7-20]. The significance of
Wingless (Wnt) proteins in susceptibility to JIA was con-
firmed in a study of polymorphisms in the Wnt-1-inducible
signalling pathway protein 3 (WISP3) [21]. To the best of
our knowledge, no study related to circulating sclerostin or
Dkk1 in patients with JIA has been published to date.
In the present study, we assessed bone mineral density
(BMD) at standard skeletal sites, as well as biochemical
markers of osteoclast, osteoblast and osteocyte function,
in patients with persistent high-activity JIA. These param-
eters were assessed at baseline and after 12 months and
24 months of treatment with tumour necrosis factor αioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in the study. The objective of the study was to evaluate
factors that predict BMD alterations in young adult pa-
tients with active JIA being treated with TNFα inhibitors.Methods
Study population
We conducted a prospective, open-label study in 2009
and 2010. We enrolled 31 patients with JIA (12 males and
19 females) with a mean age of 25.1 ± 6.1 years who had
high disease activity determined on the basis of high-
sensitivity C-reactive protein (hsCRP) level, erythrocyte
sedimentation rate (ESR) and Disease Activity Score in 28
joints (DAS28). All of the included patients met the cri-
teria of the Czech Rheumatology Society for treatment
with TNFα inhibitors. At baseline, the patients were naive
to anti-TNFα therapy. The basic condition for inclusion in
the study was high disease activity expressed by DAS28 ≥
3.9. Another precondition was inadequate response to one
disease-modifying antirheumatic drug [22].
At the time of patient selection, a group of healthy con-
trol participants was recruited from amongst the friends,
acquaintances and colleagues of the patients with JIA. In
total, 100 healthy males and females were examined. Each
patient with JIA was matched with three suitable control
participants on the basis of sex and age (in most cases
within a 2-year age difference and in isolated cases within
a maximum age difference of 6 years). Nine female
patients with JIA were matched with two control partici-
pants only. In this manner, 84 age- and sex-matched con-
trol participants were selected. All study participants were
examined and treated at the Institute of Rheumatology in
Prague.
The study was conducted in accordance with the World
Medical Association Declaration of Helsinki regarding
ethical conduct of research involving human subjects. The
study was approved by the ethics committee of the Insti-
tute of Rheumatology, and all participants gave us their
written informed consent before enrolment.Clinical parameters
The baseline clinical status of the patients with JIA was
established on the first day of TNFα inhibitor treatment.
A physical examination, blood testing and BMD testing
were performed on day 1 and again at 12 and 24 months.
Detailed information about each patient’s JIA disease
course and treatment, as well as personal history, family
history and fracture risk factor assessment, was obtained
from the patient and the available medical documentation.
A physical examination of the patients with JIA was
performed at each visit, and the number of swollen and
tender joints was documented. Body height was mea-
sured using a stadiometer. Body weight was measuredusing an exact scale. The control participants were ex-
amined in a similar manner.
The patients with JIA were given daily supplements of
1,000 mg of calcium and 800 IU of vitamin D for a mini-
mum of 6 months before the start of anti-TNFα treatment.
The control participants did not receive any calcium or
vitamin D supplements.
To maintain the same conditions for the collection of
blood samples, patients and control participants were
instructed to fast for 12 hours overnight while maintaining
adequate hydration. At 8:00 the following morning, venous
blood was collected into regular laboratory serum tubes by
antecubital venepuncture. For the purposes of soluble
receptor activator of nuclear factor κB ligand (sRANKL),
osteoprotegerin (OPG), Dkk1 and sclerostin assays, aliquots
of blood serum were frozen and stored at −80°C until
analysis after the study was completed. Other laboratory
parameters were measured on the day of blood collection.
For the purpose of determining JIA activity, the DAS28
score was calculated using objective clinical components
(the number of swollen and tender joints among the total
of 28 joints assessed), laboratory components (ESR in
millimetres per hour) and subjective components (patient
global health analogue scale, mm) (PGH).
Laboratory methods
The hsCRP concentration was measured by immunoturbi-
dimetry. The interassay coefficient of variation was 1.9%.
The sRANKL, OPG, Dkk1 and sclerostin serum concen-
trations were measured using enzyme-linked immuno-
sorbent assay (ELISA) kits in compliance with the
manufacturer’s instructions, always by the same person.
The results were read using the Tecan Sunrise ELISA
reader (Tecan, Männedorf, Switzerland). All samples were
analysed in duplicates. The sRANKL ELISA (Biomedica
Medizinprodukte, Vienna, Austria) was performed to de-
tect free sRANKL without the OPG bond; intra- and
interassay coefficients of variation were 9% and 3%, re-
spectively; and the limit of detection was 0.02 pmol/L.
The serum OPG ELISA (Biomedica Medizinprodukte)
intra- and interassay coefficients of variation were 10%
and 7%, respectively, and the limit of detection was 0.14
pmol/L. The Dkk1 ELISA (Biomedica Medizinprodukte)
intra- and interassay coefficients of variation were 7% and
8%, respectively, and the limit of detection was 0.38 pmol/
L. The serum sclerostin ELISA kit (Uscn Life Science,
Wuhan, China/Cloud-Clone, Houston, TX, USA) has no
significant cross-reactivity or interference between human
sclerostin and analogues; the standard curve is read be-
tween 0.312 and 20 g/L. The limit of detection was
0.106 g/L, and the intra- and interassay coefficients of
variation were <10% and <12%, respectively.
The bone metabolism markers osteocalcin (OC), procol-
lagen type I N-terminal propeptide (PINP), C-terminal
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min D3 were measured using electrochemiluminescence-
based immunoanalysis (cobas analyzer; Roche Diagnostics,
Mannheim, Germany). The intraassay coefficient of vari-
ation for OC was <5% at concentrations between 11 and
40 μg/L. The intraassay coefficient of variation for PINP
was <5%, and the interassay coefficient of variation was
<7%, at concentrations between 20 and 90 μg/L. The
intraassay coefficient of variation for βCTX-I was <7% for
samples between 200 and 500 ng/L and <10% for very low
βCTX-I concentration samples. The interassay coefficient of
variation for βCTX-I was <9% for samples between 200 and
500 ng/L. The detection limit for βCTX-I was <10 ng/L.
Imaging parameters
Radiographs of the thoracic and lumbar spine (anteropos-
terior and lateral) were obtained. BMDs of the lumbar
spine, proximal hip, femoral neck and distal forearm were
measured by dual-energy X-ray absorptiometry using a
bone densitometer (Prodigy; GE Healthcare, Waukesha,
WI, USA). The same technician performed all measure-
ments using the same instrument, and the same physician
performed all assessments. The short-term in vivo coeffi-
cients of variation for lumbar spine, total femur, femoral
neck and distal radius were 0.7%, 0.9%, 1.8% and 0.9%, re-
spectively. The long-term coefficient of variation using the
Hologic phantom was 0.31%. Daily scanning of a phantom
showed an absence of machine drift during the study.
BMD was expressed in grams per square centimetre.
Statistical analysis
Data for continuous variables were expressed as the mean
± SD or the median with a 75% confidence interval (CI).
Bivariate analyses were performed by using Student’s t-test
and Pearson’s correlation coefficients to analyse the rela-
tionships between the dependent variables. Following
anti-TNFα treatment, changes in the monitored parame-
ters (BMD at individual skeletal locations at 12 and
24 months, laboratory parameters at 6, 12 and 24 months)
were compared using one-way repeated-measures analysis
of variance (ANOVA). These changes in the JIA group
were compared with those in the control group by using
one-way ANOVA. A stepwise multiple linear regression
analysis was performed to create a multivariate summary
model of the determinants of dependent variables. All as-
sumptions of the linear regression analysis were also ex-
amined. Results at the level of P =0.05 were considered
significant. All analyses were performed using a SigmaPlot
10 software package (Systat Software, Erkrath, Germany).
Results
The basic clinical and laboratory characteristics of the par-
ticipants are listed in Tables 1, 2 and 3. In female patients
with JIA, the average age of menarche was 13.1 ± 1.2 years.No significant differences in anthropometric parameters
were observed between the control participants and pa-
tients with JIA. In males and females with JIA, significant
sex-based differences were identified in body height,
DAS28 score, OC, PINP, βCTX-I and BMD in the distal
radius (Table 2). In patients with JIA, the disease had been
diagnosed at approximately age 10.3 ± 4.8 years, and it
had lasted on average for 14.6 ± 9.1 years at the time of
the study. The cervical spine was affected in seven pa-
tients. None of the patients in the study had vasculitis or
lung impairment. Six patients tested positive for antinu-
clear antibodies. The polyarticular form of JIA was present
in sixteen patients. Four patients were rheumatoid factor–
positive, and twelve were rheumatoid factor–negative. The
enthesitis-related form of JIA was present in nine patients;
the extended oligoarticular form was present in four pa-
tients; and the psoriatic form was present in two patients.
Eighteen patients were in functional class I, four were in
functional class II, five were in functional class III and four
were in functional class IV. The mean Health Assessment
Questionnaire score (1978) was 0.97 ± 0.60, and the mean
EuroQol questionnaire score 5D was 0.56 ± 0.27. Before the
start of anti-TNFα treatment, all of the patients with JIA
were treated with disease-modifying antirheumatic drugs.
Twenty-three patients were given methotrexate at an aver-
age dose of 16.8 ± 3.4 mg/wk; four patients were treated
with leflunomide, two patients were treated with
sulphasalazine; one patient was treated with sulphasalazine
and hydroxychloroquine sulphate; and one patient was
treated with cyclosporine A. Twelve patients were receiving
glucocorticoid therapy (prednisone in ten patients and
methylprednisolone in two patients). The average daily dose
of glucocorticoids was 6.6 ± 4.3 mg; the median dose was
5 mg/day; and the dose range was 4 to 20 mg/day. Fourteen
of the patients with JIA had taken glucocorticoids in the
past, but did not during the course of this study. Five of the
patients with JIA did not take glucocorticoids at any time.
At baseline, the BMD values (g/cm2) in all of the
measured skeletal locations in patients with JIA were
significantly lower compared to the healthy control par-
ticipants (Table 3). A significant negative correlation be-
tween BMD in the femoral neck and the use of
glucocorticoids (r = −0.40, P <0.05) and the disease dur-
ation (r = −0.48, P <0.005) was established for the base-
line values. There was a statistically significant positive
correlation between Dkk1 (r =0.36, P <0.05) and disease
activity expressed by means of hsCRP. Following adjust-
ment for sex, glucocorticoid treatment and disease
duration, there was a significant correlation between
DAS28 values and levels of OC (P =0.005) and OPG
(P =0.32), but not βCTX-I. The baseline βCTX-I values
were dependent on sex only (P <0.001). No significant
association between sclerostin serum concentrations
and other monitored variables was found, except for a







Males/females (n) 12/19 36/48 0.692
Age (yr) 25.1 ± 6.1 23.8 ± 4.5 0.405
Height (cm) 170.5 ± 9.8 173.3 ± 9.3 0.145
Weight (kg) 68.0 ± 12.5 69.2 ± 12.5 0.884
BMI (kg/m2) 23.4 ± 3.9 22.9 ± 3.0 0.435
Vertebral fractures (n) 5 0 <0.001
Nonvertebral fractures (n) 6 0 <0.001
Family hip fracture history (n) 0 0
Smoking (n) 7 13 0.372
Alcohol abuse (n) 0 0
Glucocorticoids (n) 12 0 <0.001
Menarche (yr) 13.1 ± 1.2 12.9 ± 1.1 0.994
Contraception in females (n) 11 23 0.462
25(OH)D (nmol/L) 54.3 2.4 0.029
(20.2 to 168.7) (30.7 to 64.9)
PTH (pmol/L) 4.8 5.9 0.004
(1.3 to 8.8) (4.7 to 7.6)
Oestradiol (pmol/L) 98.7 103.2 0.438
(18.4 to 541.1) (56.4 to 260.3)
aDisplayed are numbers or means ± SD and/or medians and 75% CIs. Characteristics with zero value were not statistically calculated. BMI: Body mass index; JIA:
Juvenile idiopathic arthritis; 25(OH)D: 25-hydroxyvitamin D3; PTH: Parathyroid hormone.
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concentrations, following adjustment for sex (P =0.022).
In the course of the study, 18 patients were treated with
infliximab, 8 patients were treated with etanercept and 5
patients were treated with adalimumab. The values of in-
dividual variables are provided in Table 3. The correlations
among variables measured at baseline and in the course of
treatment are given in Table 4.
The values of BMD (g/cm2) increased in all of the mea-
sured skeletal locations compared to baseline values after
the first year and after the second year of TNFα inhibitor
treatment, respectively, by 2.9 ± 4.7% and by 4.6 ± 6.3% in
the lumbar spine, by 0.8 ± 3.2% and by 1.0 ± 4.0% in the
total proximal femur, and by 0.3 ± 3.9% and by 1.1 ± 5.0% in
the femoral neck. However, the BMD increase was signifi-
cant in the lumbar spine only (Table 3). An increase in
spinal BMD after 2 years was significantly predicted by a re-
duction in DAS28 score after the first year of treatment
(P =0.003), and this correlation did not change after adjust-
ment for sex, age, body height, treatment with glucocorti-
coids or disease duration (Figure 1). Even after 2 years of
TNFα inhibitor treatment, however, the lumbar spine BMD
remained lower than that in the control group (Table 3).
Before the start of anti-TNFα treatment, serum sclerostin
concentrations were significantly higher than those in thecontrol group. Serum sclerostin dropped significantly after
as little 1 year of treatment (Table 3). Serum sclerostin
concentrations did not correlate with ESR or hsCRP levels
(Table 4). A significant correlation was found between the
number of tender joints and serum sclerostin concentra-
tion after adjustment for ESR, sex and glucocorticoid
therapy (r =0.40, P <0.001). The correlation between the
values of DAS28 and serum sclerostin concentration be-
fore treatment and during anti-TNFα treatment (Figure 2,
Table 4) remained significant after adjustment for treat-
ment with glucocorticoids (r =0.37, P =0.002). There was
a significant positive correlation between hsCRP levels
(after adjustment for treatment with glucocorticoids) and
Dkk1 serum concentrations (r =0.40, P <0.001) after
2 years of anti-TNFα treatment.
A significant negative correlation was observed between
serum βCTX-I concentrations and BMD at the total prox-
imal femur (r=−0.44, P <0.001) and the femoral neck
(r=−0.41, P <0.001). These correlations lost their signifi-
cance after adjustment for age, sex, body height, disease dur-
ation and treatment with glucocorticoids, however.
Discussion
Testing of patients with JIA with high disease activity con-
firmed that they had significantly lower BMD in all of the






Age (yr) 21 26 0.079
(19.75 to 26.5) (20.5 to 32.8)
Height (cm) 178.8 ± 7.6 165.2 ± 7.0 <0.001
Weight (kg) 73.3 ± 11.7 64.6 ± 12.1 0.059
BMI (kg/m2) 22.9 ± 2.9 23.7 ± 4.5 0.559
Disease duration (yr) 11.0 ± 8.2 16.9 ± 9.4 0.087
Vertebral fractures (n) 3 2
Nonvertebral fractures (n) 2 4
Smoking (n) 3 4
Glucocorticoids (n) 3 9 0.230
Menarche (yr) 13.1 ± 1.2
Contraception (n) 11
hsCRP (mg/L) 9.65 13.78 0.395
(5.84 to 44.78) (6.78 to 24.21)
DAS28 6.07 6.44 0.041
(5.63 to 6.52) (6.15 to 7.04)
ESR (mm/hr) 24.5 26.0 0.670
(17.0 to 54.0) (24.0 to 34.5)
Swollen joints (n) 11.0 12.0 0.263
(7.5 to 13.5) (9.0 to 18.3)
Tender joints (n) 13.5 17.0 0.038
(10.0 to 15.0) (12.3 to 21.5)
PGH (mm) 67.5 69.0 0.947
(60.0 to 74.5) (53.8 to 77.5)
Osteocalcin (μg/L) 24.3 14.3 0.016
(20.2 to 28.0) (11.3 to 23.0)
PINP (μg/L) 57.6 40.1 0.003
(46.3 to 85.6) (19.9 to 46.4)
βCTX-I (μg/L) 0.54 0.23 <0.001
(0.43 to 0.87) (0.14 to 0.36)
PTH (pmol/L) 4.08 4.80 <0.001
(1.73 to 6.05) (2.50 to 6.15)
Lumbar spine BMD (g/cm2) 1.018 1.075 0.392
(0.913 to 1.201) (1.012 to 1.221)
Total femur BMD (g/cm2) 0.938 0.877 0.073
(0.887 to 1.131) (0.764 to 0.916)
Femoral neck BMD (g/cm2) 0.934 0.875 0.092
(0.853 to 1.132) (0.805 to 0.948)
Distal radius BMD (g/cm2) 0.751 0.667 0.030
(0.677 to 0.792) (0.606 to 0.704)
aDisplayed are numbers or means ± SD and/or medians and 75% CIs. BMD: Bone mineral density; BMI: Body mass index; βCTX-I: C-terminal telopeptide of collagen
type I; DAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; hsCRP: High-sensitivity C-reactive protein; JIA: Juvenile idiopathic arthritis; 25
(OH)D: 25-hydroxyvitamin D3; PINP: Procollagen type I N-terminal propeptide; PTH: Parathyroid hormone; PGH: patient global health.
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Table 3 Disease activity, bone mineral density and laboratory variables in patients with juvenile idiopathic arthritis
during tumour necrosis factor α blocker treatment and in control participantsa
0 (n =31) 12 months (n =31) 24 months (n =31) Control participants (n =83)
hsCRP (mg/L) 12.09b 5.19b 4.28b 0.73
(6.28 to 25.17) (1.30 to 12.89) (0.89 to 13.44) (0.27 to 1.78)
ESR (mm/hr) 25.50b 16.00b 12.00b,c 4.00
(20.00 to 36.00) (4.00 to 24.00) (4.00 to 26.00) (2.00 to 8.00)
DAS28 6.26 2.93c 2.51c
(5.87 to 6.82) (1.13 to 3.69) (1.25 to 3.64)
Swollen joints (n) 12.0 0.0c 0.0c
(9.0 to 15.5) (0.0 to 2.0) (0.0 to 2.0)
Tender joints (n) 15.0 1.0c 0.0c
(11.3 to 17.8) (0.0 to 2.0) (0.0 to 2.0)
PGH (mm) 69.0 18.0c 10.0c
(59.0 to 75.0) (5.0 to 27.8) (0 to 20.0)
Lumbar spine BMD (g/cm2) 1.065b 1.089b,c 1.093b,c 1.209
(0.972 to 1.221) (1.044 to 1.248) (1.053 to 1.161) (1.175 to 1.279)
Femur total BMD (g/cm2) 0.909b 0.918b 0.886b 1.134
(0.776 to 0.984) (0.776 to 1.015) (0.790 to 0.996) (1.061 to 1.202)
Femoral neck BMD (g/cm2) 0.899b 0.903b 0.905b 1.118
(0.819 to 1.017) (0.806 to 1.033) (0.821 to 1.019) (1.042 to 1.201)
Distal forearm BMD (g/cm2) 0.690 0.712 0.707 0.713
(0.614 to 0.761) (0.638 to 0.769) (0.632 to 0.762) (0.676 to 0.768)
Osteocalcin (μg/L) 17.75 17.45 15.20 21.20
(12.40 to 24.80) (8.80 to 26.90) (11.95 to 20.20) (16.68 to 26.90)
PINP (μg/L) 46.16 46.41 51.23 50.96
(31.96 to 59.41) (32.01 to 88.77) (33.66 to 72.01) (37.10 to 81.84)
βCTX-I (μg/L) 0.35 0.33 0.33b 0.46
(0.18 to 0.52) (0.23 to 0.49) (0.20 to 0.45) (0.34 to 0.70)
sRANKL (pmol/L) 0.08 0.05 0.07 0.06
(0.02 to 0.25) (0.00 to 0.25) (0.00 to 0.21) (0.00 to 0.16)
OPG (pmol/L) 3.84 3.26 3.02 3.14
(2.53 to 4.84) (2.10 to 3.64) (2.03 to 3.55) (2.62 to 3.85)
sRANKL/OPG ratio 0.03 0.03 0.01 0.02
(0.01 to 0.07) (0.00 to 0.10) (0.00 to 0.10) (0.00 to 0.05)
Dkk1 (pmol/L) 28.74 24.08 21.52b,c 28.74
(23.8 to 36.84) (14.54 to 29.41) (15.72 to 31.25) (23.80 to 36.84)
Sclerostin (μg/L) 7.42b 2.06c 1.22c 1.94
(3.57 to 15.49) (1.00 to 3.48) (0.30 to 3.26) (0.62 to 5.71)
aBMD: Bone mineral density; BMI: Body mass index; βCTX-I: C-terminal telopeptide of collagen type I; DAS28: Disease Activity Score in 28 joints; PGH: patient global
health; Dkk1: Dickkopf Wnt signalling pathway inhibitor 1; ESR: Erythrocyte sedimentation rate; hsCRP: High-sensitivity C-reactive protein; JIA: Juvenile idiopathic
arthritis; 25(OH)D: 25-hydroxyvitamin D3; OPG: Osteoprotegerin; PINP: Procollagen type I N-terminal propeptide; PTH: Parathyroid hormone; sRANKL: Soluble receptor
activator of nuclear factor κB ligand. bMedian and 75% CI with probability P <0.05 by means of one-way analysis of variance, as compared to control participants.
cMedian and 75% CI with probability P <0.05 by means of repeated-measures one-way analysis of variance within JIA group, as compared to baseline.
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BMD in the proximal femur depended upon disease dur-
ation and treatment with glucocorticoids [23,24]. During
anti-TNFα treatment, BMD increased. A significant increasein the lumbar spine BMD after 2 years of treatment corre-
lated with the drop in DAS28 values [25,26]. However,
BMD changes should be interpreted with caution, as we did
not follow up BMD in control participants, and it is unclear






Dkk1 Sclerostin hsCRP DAS28 ESR Tender joint
counts
Sex 0.226b 0.311c 0.074 0.350c 0.281c −0.029 −0.124 0.280 0.085c 0.211b
GCs 0.130 0.274c 0.391d 0.291c 0.229b 0.229b 0.416d 0.330c 0.323c
Duration 0.176 −0.500d −0.021 0.010 0.100 0.192 0.100 0.104
Lumbar spine BMD 0.512d −0.106 −0.178 −0.055 −0.121 −0.075 −0.071
Femoral neck BMD 0.017 −0.154 −0.113 −0.270b −0.266b −0.116
Dkk1 0.026 0.402d 0.113 0.244 0.071
Sclerostin −0.011 0.317c 0.023 0.332c
hsCRP 0.318c 0.751d 0.089
DAS28 0.594d 0.857d
ESR 0.255b
aBMD: Bone mineral density; DAS28: Disease Activity Score in 28 joints; Dkk1: Dickkopf Wnt signalling pathway inhibitor 1; ESR: Erythrocyte sedimentation rate;
GCs: Glucocorticoids; hsCRP: High-sensitivity C-reactive protein. bP <0.05; cP <0.005; dP <0.001.
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thermore, hip BMD remained unchanged and lower than in
control participants.
At baseline, there was a significant positive correlation
between DAS28 values and the serum concentrations of
sclerostin, as well as with hsCRP, but no significant asso-
ciation between the values of hsCRP and sclerostin was
established in this study. The association between base-
line values of DAS28 and serum concentrations of OC,
but not βCTX-I, suggests the inhibition of new bone
mass formation in active inflammatory JIA. This is con-
sistent with the finding that etanercept is able to activate
osteoblastogenesis and new bone formation by means ofFigure 1 Correlation between percent change in Disease Activity S
bone mineral density after 2 years of tumour necrosis factor α in
24 months = −1.582 − (0.112 × ΔDAS28 after 12 months) (r =0.53, P =0.0Dkk1 inhibition in the rheumatoid arthritis (RA) rat
model [27].
Sclerostin serum concentrations depend on genetic as-
pects, as well as age, sex, adiposity, kidney function and
presence of diabetes mellitus [28]. In the present study,
the use of an age-homogeneous group of young individ-
uals obviated effect of age on sclerostin levels [29,30].
Although the treated patients with JIA exhibited signifi-
cantly higher sclerostin serum concentrations than the
control participants, no significant association between
sclerostin serum concentration and any other monitored
variable (for example, BMD) was found at baseline. In
an arthritis mouse model, sclerostin inhibition resultedcore in 28 joints after 1 year and change in lumbar spine
hibitor treatment. Change in bone mineral density (BMD) after
03). DAS28: Disease Activity Score in 28 joints.
Figure 2 Correlation between the values of Disease Activity Score
in 28 joints and serum sclerostin concentration before treatment
and during tumour necrosis factor α inhibitor treatment. Disease
Activity Score in 28 joints (DAS28) =3.332 + (0.104 × sclerostin) (r =0.32,
P =0.002). Filled circles: baseline values; open triangles: 1 year of
treatment; open squares: 2 years of treatment.
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sary, however, to point out that the values of sclerostin
serum concentrations depend on the type of immunoana-
lysis used for measurement [33]. The literature reveals
contradictory results concerning the association between
sclerostin serum concentrations and BMD of the femoral
neck in postmenopausal women [29,30,34,35]. The associ-
ation between serum sclerostin and the risk of fractures
was established in two studies in postmenopausal women
[36,37], but was not evidenced in another study [34].
Significant reduction in the expression of sclerostin
occurs during mechanical loading of the skeleton
[38,39]. Sclerostin is not a specific product of osteo-
cytes, however [40]. Sclerostin is also produced by
chondrocytes and cementocytes [38,41], as well as in
the liver, vascular wall and kidney [42,43]. Our present
study in young adults with active JIA provides evidence
of an association between sclerostin serum concentra-
tions and the disease activity assessed by DAS28 values,
but not by hsCRP values. Although sclerostin and Dkk1
represent relevant inhibitors of the Wnt signalling path-
way and subsequently of new bone mass formation by
osteoblasts [8,44-46], causal dependence between the
known biological effect of sclerostin (inhibition of new
bone formation) and BMD was not evidenced in our pa-
tients. Both subchondral bone cells and chondrocytes
may be sources of circulating sclerostin patients with JIA.
This hypothesis is supported by the finding that, in the
RA model, the sclerostin inhibition by a monoclonal anti-
body protects the bone and cartilage from inflammatory
damage [31]. This hypothesis is further supported by a sig-
nificant correlation between serum sclerostin and the
number of tender and swollen joints, as established in ourstudy, whereas no significant correlation between serum
sclerostin and hsCRP, ESR or Dkk1 has been identified.
Although baseline serum Dkk1 levels were not increased
in patients with JIA compared to healthy control partici-
pants, there was a significant positive correlation between
Dkk1 levels and disease activity expressed by hsCRP. The re-
lationship between hsCRP and Dkk1 values was confirmed
by a significant drop in both of these markers after 2 years
of treatment. A similar dependence between hsCRP and
Dkk1, as well as a drop in both variables, was previously de-
scribed in patients with RA treated with infliximab [20]. The
patients with JIA in our study did not exhibit any significant
relationship between the Dkk1 serum concentrations and
any of the other monitored variables at baseline or during
treatment with TNFα inhibitors.
In this study, we did not find any significant increase in
the serum concentrations of sRANKL, OPG or their ratio in
patients with JIA compared to healthy control participants.
Although studies in RA most often evidence increased
sRANKL concentrations [47-49], unchanged concentrations
have also been established [50]. In children with JIA, a de-
crease in RANKL and an increase in OPG have been dem-
onstrated [51]. In other studies of various JIA subtypes,
researchers have mentioned an increase in serum as well as
synovial fluid sRANKL [15,52-54]. In the present study,
sRANKL values of zero were included in the analyses, unlike
in some other studies [52,54]. Also, published data about
OPG serum concentrations in JIA differ to a high degree,
whether they are unchanged [53], increased [51,52] or de-
creased [15,54]. After TNFα blocker treatment, we did not
observe any deviation from baseline sRANKL levels, OPG
levels or their ratio. In other studies, investigators have men-
tioned both sRANKL increases and decreases during treat-
ment with TNFα blockers [55,56]. Similarly, researchers in
other studies have described no changes in OPG concentra-
tions during treatment with infliximab or etanercept [55,56].
The advantage of the present study is the prospective
follow-up of an age-homogeneous group of both patients
and healthy control individuals of both sexes and the testing
of a range of variables that describe the quantity, remodel-
ling and regulation of bone mass. The study is limited by
the low number of patients with highly heterogeneous ther-
apy, the use of only a single method of sclerostin serum con-
centration measurement and a lack of information about
the source of sclerostin. Further study of local subchondral
bone and cartilage expression of sclerostin could yield more
valuable information on the pathogenic role of sclerostin in
JIA. Incomplete assessment of potential confounding vari-
ables, including physical activity, also needs to be taken into
account.
Conclusion
To our knowledge, this study is the first to establish a link
between sclerostin serum concentration and the number
Brabnikova-Maresova et al. Arthritis Research & Therapy 2014, 16:460 Page 9 of 10
http://arthritis-research.com/content/16/5/460of tender and swollen joints in patients with JIA. Further-
more, these data support the hypothesis that chondrocytes
and cells of the subchondral bone may contribute to cir-
culating sclerostin.
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